# A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage II and Stage III Colon Cancer and dMMR/MSI.

Source: https://onco.cc/trials/nct05231850/  
OnCo record `nct05231850` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of tislelizumab in colorectal cancer, run by The First Affiliated Hospital of Zhengzhou University, not yet recruiting.

## Summary

A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage II and Stage III Colon Cancer and dMMR/MSI. is a phase 2, interventional study registered as NCT05231850 by The First Affiliated Hospital of Zhengzhou University, with a registry enrolment figure of 70 participants, started 2022-03-01 and due to reach its primary completion in 2023-09-01. Interventions recorded: Tislelizumab. Conditions listed: Colon Cancer. Primary outcome: Primary End point: Disease Free survival [ Time Frame: 3 years ]. Colorectal eligibility wording from the registry: ", any T, N1 or N2, M0) adenocarcinoma of the colon (as defined by the presence of the inferior pole of the tumour above the peritoneal reflection - that is, at least 15 cm from the anal margin)". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05231850
- Phase: 2
- Setting: A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With High-risk Stage II and Stage III Colon Cancer and Deficient Mismatch Repair or Microsatellite Instability.
- Sponsor: The First Affiliated Hospital of Zhengzhou University
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT05231850: https://clinicaltrials.gov/study/NCT05231850

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05231850.json